Clinical Profile, Intensive Care Needs, and Short-Term Outcome of Toxic Shock Syndrome Among Children: A 10-Year Single-Centre Experience from North India
- PMID: 35804287
- PMCID: PMC9266086
- DOI: 10.1007/s12098-022-04271-4
Clinical Profile, Intensive Care Needs, and Short-Term Outcome of Toxic Shock Syndrome Among Children: A 10-Year Single-Centre Experience from North India
Abstract
Objective: To describe the clinical and laboratory profile, management, intensive care needs, and outcome of children with toxic shock syndrome (TSS) admitted to the pediatric intensive care unit (PICU) of a tertiary care center in North India.
Methods: This retrospective study was conducted in the PICU of a tertiary care hospital in North India over a period of 10 y (January 2011-December 2020) including children < 12 y with TSS (n = 63).
Results: The median (interquartile range, IQR) age was 5 (2-9) y, 58.7% were boys, and Pediatric Risk of Mortality III (PRISM-III) score was 15 (12-17). The primary focus of infection was identified in 60.3% children, 44.5% had skin and soft tissue infections, and 17.5% (n = 11) had growth of Staphylococcus aureus. Common manifestations were shock (100%), rash (95.2%), thrombocytopenia (79.4%), transaminitis (66.7%), coagulopathy (58.7%), and acute kidney injury (AKI) (52.4%); and involvement of gastrointestinal (61.9%), mucus membrane (55.5%), respiratory (47.6%), musculoskeletal (41.3%), and central nervous system (CNS) (31.7%). The treatment included fluid resuscitation (100%), vasoactive drugs (92.1%), clindamycin (96.8%), intravenous immunoglobulin (IVIG) (92.1%), blood products (74.6%), mechanical ventilation (58.7%), and renal replacement therapy (31.7%). The mortality was 27% (n = 17). The duration of PICU and hopsital stay was 5 (4-10) and 7 (4-11) d, respectively. Higher proportion of nonsurvivors had CNS involvement, transaminitis, thrombocytopenia, coagulopathy, and AKI; required mechanical ventilation and blood products; and had higher vasoactive-inotropic score.
Conclusion: TSS is not uncommon in children in Indian setup. The management includes early recognition, intensive care, antibiotics, source control, and adjunctive therapy (IVIG and clindamycin). Multiorgan dysfunction and need for organ supportive therapies predicted mortality.
Keywords: Clindamycin; Intravenous immunoglobulin; Mechanical ventilation; Shock; Staphylococcus aureus; Vasoactive drugs.
© 2022. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation.
Conflict of interest statement
None.
Comment in
-
Toxic Shock Syndrome: A Diagnostic and Therapeutic Challenge!Indian J Pediatr. 2023 Apr;90(4):321-322. doi: 10.1007/s12098-023-04478-z. Epub 2023 Jan 13. Indian J Pediatr. 2023. PMID: 36635581 Free PMC article. No abstract available.
References
-
- Noorbakhsh S, Rabiei AA, Rahbarimanesh AA, Haghighi M, Ashouri S. Searching the staphylococcal toxic shock syndrome toxin -1 in septic children with negative cultures: a comparative study in Tehran. Iran Infect Disord Drug Targets. 2021;21:187–192. doi: 10.2174/1871526520666200731180641. - DOI - PubMed
-
- Adalat S, Dawson T, Hackett SJ, Clark JE. In association with the British Paediatric Surveillance U. Toxic shock syndrome surveillance in UK children. Arch Dis Child. 2014;99:1078–82. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
